SCHEMBL7380988

SCHEMBL7380988

[NH]CC1Cc2ccccc2O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.49
AOC2 O75106 5/20 0.41
MAOA P21397 5/20 0.41
MAOB P27338 5/20 0.41
DAO P14920 1/20 0.41
CA2 P00918 2/20 0.40
NISCH Q9Y2I1 1/20 0.40
HTR1A P08908 2/20 0.39
HTR1D P28221 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968939 0.81 CA2 (0.55) CA2HTR1AHTR1DADRA2AADRA2B
SCHEMBL8405409 0.81 HRH3 (0.37) HRH3AOC2MAOAMAOBDAO
SCHEMBL9935891 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO
SCHEMBL4231394 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO
SCHEMBL29841223 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO
SCHEMBL434338 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO
SCHEMBL6723015 0.80 HRH3 (0.53) HRH3AOC2MAOAMAOBDAO
SCHEMBL4526675 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO
SCHEMBL10736602 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO
SCHEMBL17193879 0.80 HRH3 (0.49) HRH3AOC2MAOAMAOBDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1150979-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-07 EP claimed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US claimed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 HRH3 392/4885AOC2 2029/4885MAOA 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.